Mitosol(R)'s Orphan Drug Designation is Expanded for All Glaucoma Surgery

St. Louis ophthalmic company expands designation to include all glaucoma surgery ST. LOUIS, Oct. 31, 2017 -- (Healthcare Sales & Marketing Network) -- Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has expanded its Orphan Drug Designa... Biopharmaceuticals, Ophthalmology, FDA Mobius Therapeutics, Mitosol, mitomycin, glaucoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news